|Bid||0.5600 x 40000|
|Ask||0.6074 x 40000|
|Day's Range||0.5425 - 0.5430|
|52 Week Range||0.4902 - 2.8100|
|Beta (3Y Monthly)||0.29|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.
The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.